HeXun Biosciences Co., Ltd.
HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.
HeXun Biosciences Co., Ltd. (6986) - Total Assets
Latest total assets as of September 2025: NT$792.78 Million TWD
Based on the latest financial reports, HeXun Biosciences Co., Ltd. (6986) holds total assets worth NT$792.78 Million TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HeXun Biosciences Co., Ltd. - Total Assets Trend (2020–2024)
This chart illustrates how HeXun Biosciences Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
HeXun Biosciences Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
HeXun Biosciences Co., Ltd.'s total assets of NT$792.78 Million consist of 68.4% current assets and 31.6% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 28.4% |
| Accounts Receivable | NT$84.68 Million | 12.0% |
| Inventory | NT$15.58 Million | 2.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$26.67 Million | 3.8% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how HeXun Biosciences Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HeXun Biosciences Co., Ltd.'s current assets represent 68.4% of total assets in 2024, an increase from 29.6% in 2020.
- Cash Position: Cash and equivalents constituted 28.4% of total assets in 2024, up from 26.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 12.0% of total assets.
HeXun Biosciences Co., Ltd. Competitors by Total Assets
Key competitors of HeXun Biosciences Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
HeXun Biosciences Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - HeXun Biosciences Co., Ltd. generates 0.41x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, HeXun Biosciences Co., Ltd. generates $ 20.83 in net profit.
HeXun Biosciences Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.27 | 8.99 | 10.55 |
| Quick Ratio | 10.09 | 8.70 | 10.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$513.28 Million | NT$ 429.49 Million | NT$ 191.22 Million |
HeXun Biosciences Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between HeXun Biosciences Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.40 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 23.7% |
| Total Assets | NT$706.92 Million |
| Market Capitalization | $33.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values HeXun Biosciences Co., Ltd.'s assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: HeXun Biosciences Co., Ltd.'s assets grew by 23.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for HeXun Biosciences Co., Ltd. (2020–2024)
The table below shows the annual total assets of HeXun Biosciences Co., Ltd. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$706.92 Million | +23.71% |
| 2023-12-31 | NT$571.43 Million | +41.39% |
| 2022-12-31 | NT$404.15 Million | +37.18% |
| 2021-12-31 | NT$294.62 Million | +10.66% |
| 2020-12-31 | NT$266.24 Million | -- |